• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Metopirone (metyrapone USP) 250 mg, Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2010

Summary View

ADVERSE REACTIONS

  • Cardiovascular system: Hypotension

PRECAUTIONS:

Carcinogenesis, Mutagenesis, Impairment of Fertility
  • ...Metopirone was not mutagenic with or without metabolic activation in three strains of bacteria.
Pregnancy Category C
  • ... Animal reproduction studies adequate to evaluate teratogenicity and postnatal development have not been conducted with Metopirone.